The firm is a global chemical company founded in 1935. A subsidiary was initially established as the firm’s first U.S. representative office in NY in 1964 and has grown to become the corporation’s main sales, marketing, and business development center in North America. In addition to a variety of other markets, the firm serves the chemical, petrochemical and bioscience markets. The firm has recently started a corporate venture initiative with a $300M budget to make strategic investments into both pre and post-commercial companies. The group is flexible in terms of structuring investments and may employ equity investments, M&A and licensing agreements. The firm targets investment sizes from $100k – $5M for early stage companies and $10M-$50M for commercial-stage companies.
In terms of the healthcare and life science sectors, the firm is most interested in companies working in diagnostics and research tools. The firm is particularly interested in clinical diagnostics including IVDs and next generation platforms (NGS, liquid biopsy, LC-MS, point-of-care testing, digital PCR), separation media and connected devices and wearable medical sensors. The group is also interested in advanced materials including materials for secondary batteries, thin-film for electronic devices, separation (inorganic/organic/polymers) and composites. The firm is agnostic to indication area, but has a particular interest in cancer, metabolic (including diabetes) and kidney disorders as well as reproductive health.
The firm has no strict company or management team requirements and invest in both early and later stage opportunities. Board observer status is required along with an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply